CORC

在结果中检索

CORC

浏览/检索结果: 共141条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
含酰基和三氮唑的一枝蒿酮酸衍生物的合成及抗流感病毒活性研究 学位论文
中国科学院新疆理化技术研究所: 中国科学院大学, 2021
作者:  陈磊
收藏  |  浏览/下载：23/0  |  提交时间：2021/08/27
Overview of therapeutic drug research for COVID-19 in China 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020, 页码: 8
作者:  Li, Heng;  Yang, Li;  Liu, Fei-fei;  Ma, Xin-na;  He, Pei-lan
收藏  |  浏览/下载：16/0  |  提交时间：2020/12/24
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infectionn 期刊论文
JOURNAL OF MEDICAL VIROLOGY, 2019, 卷号: 91, 期号: 7
作者:  Huang, Rui;  Rao, Huiying;  Xie, Qing;  Gao, Zhiliang;  Li, Wu
收藏  |  浏览/下载：22/0  |  提交时间：2019/12/04
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：56/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：43/0  |  提交时间：2019/12/05
Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma 期刊论文
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 卷号: 512, 期号: 4
作者:  Xu, Mingfang;  Tao, Zezhang;  Wang, Shuai;  Jiang, Yidao;  Qu, Mei
收藏  |  浏览/下载：21/0  |  提交时间：2019/12/05
Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation 期刊论文
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 卷号: 513, 期号: 4
作者:  Hu, Zhihua;  Zhen, Lanfang;  Li, Qin;  Han, Qi;  Hua, Qinquan
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05
HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b 期刊论文
2019, 卷号: 98, 期号: 10
作者:  Fan, Zhijuan;  Liu, Junfeng;  Wang, Fengmei;  Liu, Jingmin;  Ding, Xian
收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace